Tanezumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tanezumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target NGF
Clinical data
Synonyms RN624
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6464H9942N1706O2026S46
Molar mass 145.4 kg/mol
 NYesY (what is this?)  (verify)

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another Phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]

In March of 2012, the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.[6] [7]

A Phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[8]

See also[edit]

References[edit]

External links[edit]